期刊文献+

SOX1对鼻咽癌细胞化疗敏感性的影响

Effect of SOX1 gene overexpression on chemotherapeutic sensitivity of nasopharyngeal carcinoma cells
下载PDF
导出
摘要 目的 观察SOXl基因过表达对鼻咽癌细胞化疗敏感性的影响.方法 采用脂质体Lipofectamin2000介导的方法,将SOXl基因转入鼻咽癌细胞CNE2和HONE1中,RT-PCR和Western blot法检测转染空载体对照组及转染SOX1过表达组鼻咽癌细胞中SOX1基因的表达,并用MTT法检测两组鼻咽癌细胞对化疗药物的敏感性.结果 RT-PCR和Western blot法表明,转染过表达组鼻咽癌细胞的SOX1基因的mRNA及蛋白表达水平均较对照组明显增强,MTT法结果表明过表达SOX1的鼻咽癌细胞对化疗药物顺铂的敏感性显著提高(P<0.05).结论 转染外源性SOX1并使之在鼻咽癌细胞中过表达,能提高CNE2和HONE1细胞对化疗药物的敏感性. Objective To explore the effect of overexpressed SOX1 gene upon chemotherapeutic sensitivity of nasopharyngeal carcinoma cells.Methods Via Lipofectamin2000,SOX1 gene was transfected into NPC cell lines CNE2 and HONE 1.Cellular SOX1 expression was detected by reverse transcriptionpolymerase chain reaction (RT-PCR) and Western blot analysis.MTT was employed to investigate the sensitivity of DDP treatment between NPC cells with or without SOX1 overexpression.Results RT-PCR and Western blot results demonstrated that SOX1 mRNA and protein level of CNE2-SOX1 and HONE1-SOX1 cells were significantly higher than the two NPC cell lines in control group.MTT result showed that NPC cell lines which overexpressed SOX1 were more sensitive to DDP treatment than that in control group (P 〈 0.05).Conclusion Transfection of extrinsic SOX1 gene contributes to its overexpression in CNE2 and HONE1,which can increase the chemotherapeutic sensitivity of the two NPC cell lines.
出处 《国际医药卫生导报》 2014年第14期2081-2085,共5页 International Medicine and Health Guidance News
关键词 鼻咽癌 SOX1 化疗敏感性 Nasopharyngeal Carcinoma Chemotherapeutic sensitivity
  • 相关文献

参考文献21

  • 1Zhang L, Chen QY, Liu H, et al. Emerging treatment options for nasopharyngeal carcinoma [J]. Drug Des Devel Ther, 2013, (7) : 37-52.
  • 2Wei WI, Sham JS. Nasopharyngeal carcinoma [J]. Lancet, 2005, 365 (9476) : 2041-2054.
  • 3周同冲,余宏伟,廖志伟.尼妥珠单抗联合三维适形放疗治疗复发性鼻咽癌的临床研究[J].国际医药卫生导报,2013,19(21):3257-3260. 被引量:4
  • 4Lee AW, Lin JC, Ng WT. Current management of nasopharyngeal cancer[J]. Semin Radiat Oncol, 2012, 22 (3) : 233-244.
  • 5Sarkar A, Hochedlinger K. The sox family of transcription factors : versatile regulators of stem and progenitor cell fate [J]. Ce11Stem Cell, 2013, 12 ( 1 ) : 15-30.
  • 6Elkouris M, Balaskas N, Poulou M, et al. Soxl maintains the undifferentiated state of cortical neural progenitor ceils via the suppression of Proxl-mediated cell cycle exit and neurogenesis [J]. Stem Cells, 2011, 29 ( 1 ) : 89-98.
  • 7Kan L, Israsena N, Zhang Z, et al. Soxl acts through multiple independent pathways to promote neurogenesis [J]. Dev Biol, 2004, 269 (2) : 580-594.
  • 8Lai HC, Lin YW, Huang TH, et al. Identification of novel DNA methylation markers in cervical cancer [J]. Int J Cancer, 2008, 123 (1) : 161-167.
  • 9Apostolidou S, Hadwin R, Burnell M, et al. DNA methylation analysis in liquid-based cytology for cervical cancer screening [J]. Int J Cancer, 2009, 125 (12) : 2995-3002.
  • 10Su HY, Lai HC, Lin YW, et al. An epigenetic marker panel for sereening and prognostic prediction of ovarian cancer [J]. Int J Cancer, 2009, 124 (2) : 387-393.

二级参考文献13

  • 1黄晓东,易俊林,高黎,徐国镇,金晶,杨伟志,卢泰祥,吴少雄,吴仁瑞,胡伟汉,谢伟长,韩非,高远红,高剑铭,潘建基,陈传本,朗锦义,李涛,董昱,付玉彬,樊林,李柏森,黎静,王晓怀,陈炳旭,高献书,张萍,吴湘玮,胡炳强.抗表皮生长因子受体单克隆抗体h—R3联合放疗治疗晚期鼻咽癌的Ⅱ期临床研究[J].中华肿瘤杂志,2007,29(3):197-201. 被引量:100
  • 2Talavera A,Friemann R,Gomez-Puerta S,et al.Nimotuzumah,an antitumor antibody that targets theepidermal growth factor receptor,blocks ligand bindingwhile permitting the active receptor conformation[J].Cancer Res,2009,69(14):5851-5859.
  • 3Rivera F,Vega-Villegas ME,Lopez-Brea MF,et al.Current situation of Panitumumab,Matuzumah,Nimotuzumah and Zalutumumab[J].Acta Oncol,2008,47(1):9-19.
  • 4Therasse P,Arbuck SG,Eisenhauer EA,et al.Newguidelines to evaluate the response to treatment insolid tumors.European Organization for Research andTreatment of Cancer,National Cancer Institute of theUnited States,National Cancer Institute of Canada[J].JNatl Cancer Inst,2000,92(3):205-216.
  • 5Trotti A,Byhardt R,Stetz J,et al.Common toxicitycriteria:version 2.0.an improved reference for grading theacute effects of cancer treatment:impact on radiotherapy[J].Int J Radiat Oncol Biol Phys,2000,47(1):13-47.
  • 6Cox JD,Stetz J,Pajak TF.Toxicity criteria of theRadiation Therapy Oncology Group(RTOG)and theEuropean Organization for Research and Treatment ofCancer(EORTC)[J].Int J Radiat Oncol Biol Phys,1995,31(5):1341-1346.
  • 7Rojo F,Gracias E,Villena N,et al.Pharmacodynamictrial of nimotuzumah in unresectable squamous cellcarcinoma of the head and neck:a SENDO Foundationstudy[J].Clin Cancer Res,2010,16(8):2474-2482.
  • 8Crombet-Ramos T,Rak J,Perez R,et al.Antiproliferative,antiangiogenic and proapoptotic act-ivity of h-R3:ahumanized anti-EGFR an-tibody[J].Int J Cancer,2002,101(6):567-575.
  • 9Choi HJ,Sohn JH,Lee CG,et al.A phase I study ofnimotuzumah in combination with radiotherapy in stagesIIB-IV non-small cell lung cancer unsuitable for radicaltherapy:Korean results[J].Lung Cancer,2011,71(1):55-59.
  • 10Cao XJ,Hao JF,Yang XH,et al.Prognostic valueof expression of EGFR and nm23 for locore-gionallyadvanced nasopharyngeal carcinoma[J].Med Oncol,2012,29(1):263-271.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部